Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cansino Biologics Inc (OP:CASBF)

4.440 +0.060 (+1.37%)
Streaming Delayed Price Updated: 9:30 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cansino Biologics Inc

News headline image
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Via ACN Newswire
News headline image
CanSinoBIO Launches its Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health
Via ACN Newswire
News headline image
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Via ACN Newswire
News headline image
CanSino Receives Another Strong Boost
Via ACN Newswire
News headline image
CanSinoBIO Reports Outstanding H1 2024 Performance
Via ACN Newswire
News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
Why Is CanSino Biologics (CASBF) Stock Soaring Today? ↗
CanSino Biologics shares are ripping higher on Wednesday, with CASBF stock up more than 75%. The move comes as China pushes for more vaccines. 
Via InvestorPlace
News headline image
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal ↗
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
News headline image
Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal ↗
Regor Therapeutics entered a $1.55 billion research pact with Eli & Lilly to discover therapies for metabolic disorders. Meanwhile, Beijing Avistone Pharma received a $200 million investment led by... 
Via Talk Markets
News headline image
Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs ↗
Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. It currently has a portfolio of 21 products. Zai has a market cap of $14 billion and over $1... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.